High-dose influenza vaccines overcome age-related immune dysfunction in older adults, improving protection against a leading cause of hospitalization and mortality in this population. Immunosenescence and inflammaging—chronic low-grade inflammation tied to innate immune dysregulation—impair standard vaccine responses, making enhanced formulations clinically significant for aging populations.
Key Points
- Age-related immune dysfunction reduces standard vaccine effectiveness in older adults
- High-dose formulations compensate for immunosenescence and inflammaging mechanisms
- Enhanced vaccines address a major source of hospitalization and mortality
Longevity Analysis
The immune system's capacity to mount effective responses declines predictably with age, driven by both structural immune changes and persistent inflammatory signaling that interferes with appropriate defense mechanisms. High-dose vaccines represent a targeted intervention that accounts for this biological reality rather than applying one-size-fit-all protection. Understanding how inflammatory states constrain immune function—and developing countermeasures—becomes increasingly relevant as populations age and the margin between adequate and inadequate protection narrows. This approach exemplifies how interventions must match the actual physiology of aging rather than assume younger immune competence persists.
Original published by The Lancet Healthy Longevity, by Giancarlo Icardi, Vincenzo Paolozzi.